Category:hair dyeing agents
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
Appearance: | yellow to orange amorphous solid (est) |
Assay: | 95.00 to 100.00
|
Food Chemicals Codex Listed: | No |
Melting Point: | 315.00 °C. @ 760.00 mm Hg
|
Boiling Point: | 620.80 °C. @ 760.00 mm Hg (est)
|
Flash Point: | 451.00 °F. TCC ( 232.60 °C. ) (est)
|
logP (o/w): | 2.980 (est) |
Soluble in: |
| water, 3.212 mg/L @ 25 °C (est) |
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
Preferred SDS: View |
|
Hazards identification |
|
Classification of the substance or mixture |
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
None found. |
GHS Label elements, including precautionary statements |
|
Pictogram | |
|
Hazard statement(s) |
None found. |
Precautionary statement(s) |
None found. |
Oral/Parenteral Toxicity: |
unreported-guinea pig LDLo 400 mg/kg "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
intravenous-man TDLo 7143 nL/kg SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
GASTROINTESTINAL: NAUSEA OR VOMITING American Journal of Ophthalmology. Vol. 126, Pg. 837, 1998.
intravenous-mouse LD50 300 mg/kg United States Patent Document. Vol. #4775625
unreported-mouse LDLo 600 mg/kg "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
intravenous-rabbit LDLo 300 mg/kg International Journal of Leprosy and Other Mycobacterial Diseases. Vol. 2, Pg. 257, 1934.
intraperitoneal-rat LDLo 600 mg/kg International Journal of Leprosy and Other Mycobacterial Diseases. Vol. 2, Pg. 257, 1934.
|
Dermal Toxicity: |
Not determined
|
Inhalation Toxicity: |
Not determined
|
Safety in Use Information:
Category: | hair dyeing agents |
Recommendation for ci 45350:1 usage levels up to: | | not for fragrance use.
|
|
Recommendation for ci 45350:1 flavor usage levels up to: |
| not for flavor use.
|
Safety References:
References:
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| benzoic acid, 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)- | | benzoic acid, o-(6-hydroxy-3-oxo-3H-xanthen-9-yl)- | | c.i. 45350:1 | | C.I. 45350.1 | | C.I. acid yellow 73 | | C.I. solvent yellow 94 | 9-(o- | carboxyphenyl)-6-hydroxy-3-isoxanthenone | 9-(o- | carboxyphenyl)-6-hydroxy-3h-xanthen-3-one | | D & C yellow no. 7 | | D & C yellow no. 8 | | D and C yellow no. 7 | | D&C yellow no. 7 | | dc yellow no. 7 | 3',6'- | dihydroxy-3H-spiro[2-benzofuran-1,9'-xanthen]-3-one | 3',6'- | dihydroxy-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one | 3',6'- | dihydroxyfluoran | 3',6'- | dihydroxyspiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one | 3',6'- | dihydroxyspiro(isobenzofuran-1(3H),9'(9H)-xanthen)-3-one | 3,6- | dihydroxyspiro(xanthene-9,3'-phthalide) | 3',6'- | dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one | 12,15- | dihydroxyspiro[3-hydroisobenzofuran-3,9'-xanthene]-1-one | 3',6'- | dihydroxyspiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one | 3,6- | dihydroxyspiro[xanthene-9,3'-phthalide] | | fluoran, 3',6'-dihydroxy- | 3,6- | fluorandiol | 3',6'- | fluorandiol | | fluorescein | | fluoresceine | | fluorescite | | ful-glo | | funduscein | 2-(6- | hydroxy-3-oxo-(3H)-xanthen-9-yl) benzoic acid | 2-(6- | hydroxy-3-oxo-(3H)-xanthen-9-yl)benzoic acid | 2-(6- | hydroxy-3-oxo-3H-xanthen-9-yl)-benzoic acid | 2-(3- | hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid | | japan yellow 201 | | japan yellow no. 201 | | soap yellow F | | solvent yellow 94 | | spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy- | 3H- | xanthen-3-one, 9-(o-carboxyphenyl)-6-hydroxy- |
Articles:
|
a phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal injuries and corneal trauma. it has been approved by fda for use in externally applied drugs and cosmetics. (from merck index, 12th ed; american medical association drug evaluations; 1995, p2275)
|